After the fourth year of the project
Several hundred natural extracts have been prepared from cyanobacteria, fungi
and also from plants. Activity screening of the extracts and that of pure
compounds isolated from the extracts has been done. In addition several hundred
synthetic compounds targeted to various protein kinases have been synthesised.
Groups oriented to synthetic organic chemistry (WP3) use modern methods of
organic synthesis to prepare compounds that are based on natural product
screening (WP1) or virtual screening of known chemicals (WP2). These synthesis
products can be tested in various protein kinase binding and activity assays to
find the hit molecules. This provides essential feed-back information for the
molecular modellers and synthetic chemists to refine the chemical structure of
the found hits within the iterative process of drug discovery and development.
The Protein Kinase Research Consortium (PKRC) chemical library has been
established and databases of synthesised and extracted compounds have been
generated (total of 960 compounds todate). Computational tools for generation of
3D models of protein kinases and for virtual screening of protein
kinase-targeted compounds have been developed within the Consortium. Tens of
thousands of compounds have been screened virtually and the promising hits have
been submitted for experimental validation to further testing within the
A number of the novel compounds show biological activity in various assay systems utilising purified kinase enzyme preparations. Several recombinant protein kinase domains have been expressed and used in the screening for ligand binding. Indeed, there are more than 150 different kinase activity assays available within the Consortium, thus the binding affinity and biological activity of potential protein kinase inhibitors/activators are screened with the help of extensive collaboration. Rational drug design relies on three dimensional models of proteins and more specifically of the active site – the ligand binding site. In order to determine the crystal structure of the critical binding sites of different kinases, large quantities of various protein kinases have been produced in cell cultures. Structures of different kinase/inhibitor complexes and a novel protein kinase have been solved (WP4)
Protein kinases represent a significant therapeutic target in many pathologies as they represent the effectors of cell signalling pathways that control a variety of cell functions including cell proliferation, differentiation and cell death. In WP5 various model systems for a range of diseases have been utilised to test therapeutic potential of novel compounds of both natural and synthetic origin. The diseases include cancer (with leukaemia as a specific disease targeted as well as breast cancer, glial and gastric tumours), epilepsy, heart disease and post-stroke neurodegeneration, leishmaniasis and inflammatory disease. The protein kinases that have been the focus of the project include Tyrosine Kinases (receptor and cytoplasmic), Protein kinase C, MAP kinases and Cyclin Dependent Kinases. Many partners have produced second and third generation of compounds expressing activity on selected kinases. Some partners have already started preclinical in vivo animal studies. Also larger scale synthesis of some compounds has been started.
|This year our meeting was hosted by Prof. Janet M. Lord (right) from the University of Birmingham: Here with the project coordinator Prof. Raimo K. Tuominen from University of Helsinki.|
In the fourth year crystal structures of domains of two PKC isofrom were resolved. Target kinases for the novel compounds have been studied in more detail. Also profiling of protein kinase substrate peptides in a substrate peptide chip assay has progressed. Several protein kinase inhibitors showed inhibitory activity in a vascular smooth muscle proliferation assay and therefore it is possible that in the future protein kinase inhibitors may be used in the treatment of re-stenosis after balloon surgery (angioplasty) of coronary arteries. More than 100 compounds originating from consortium laboratories have been tested in anti-parasite assays against Leishmania species. Some compounds show promising activity and this observation can open new avenues in the treatment strategies of parasite diseases in the future. Leishmanial protein kinases have also been cloned and expressed. Natural and synthetic compounds have been tested in models of leukaemia and already 3 plant-derived and 3 synthetic PKC-modulating compounds show high potency against leukaemic cells in cell culture. The effects of selected inhibitors on neuronal excitotoxicity (models of neuronal death identified during stroke) were tested and identified as neuroprotective agents. One protein kinase inhibitor was shown to display neuroprotective effect in an animal model of stroke. The lead compound and its potential successors will be further studied for a possible novel stroke therapy. Some of these inhibitors may also modulate neuronal excitability and may represent a new approach for epileptic treatment. New compounds inhibiting RET-kinase and resistant form of Abl kinase have been synthesized and tested in vitro. Molecules targeted on multidrug resistance proteins have been generated. Fifteen new protein kinase activity assays were established during the fourth year, many of which are cellular assays.
The research groups of Pro-KinaseResearch consortium represent different
disciplines of science with the same focus of interest: the protein kinases. Our
research efforts aim at the discovery of new means by which the activity of
protein kinases can be modified. Our research will increase the possibility for
development of clinically useful drugs having a novel mechanism of action. In
Europe and other areas of the world with high standard of living diseases such
as cancer, autoimmune diseases, cardiovascular diseases and neurological
diseases are an increasing threat to public health. In developing countries
parasitic infectious diseases such as malaria and leishmania are enormous health
problems. In the future, innovations based on our results can be available to a
global drug market to combat diseases mentioned above.
See also our scientific publications.